Drug · DIN 02455439
INVOKAMET
No: no longer authorized
The company stopped selling it and its DIN was cancelled. A cancellation is most often a business decision; the record does not say why.
Status Cancelled Post Market since December 9, 2024; first marketed June 28, 2016.
- Drug Identification Number (DIN)
- 02455439
- Company (DIN owner)
- Janssen Inc.Toronto, Ontario, Canada
- Schedule
- Prescription
- Dosage form
- Tablet
- Route
- Oral
- Therapeutic class (ATC)
- Metformin and canagliflozin A10BD16
- Class
- Human
- Record last updated
- March 22, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| CANAGLIFLOZIN | 150 MG | |
| METFORMIN HYDROCHLORIDE | 500 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- January 20, 2017: NOC 18900Supplement to a New Drug Submission (SNDS) · Update to the product monograph to include increased risk of bone fractures with the use of canaglifozin in response to an advisory letter
- June 1, 2016: NOC 18144New Drug Submission (NDS)
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “invokamet”. A notice may cover another product or only some lots: read it to see what it covers.
- Invokamet (2020-01-15)January 15, 2020 · Drugs · Product safety · Type III
- INVOKANA® (canagliflozin) and INVOKAMET® (canagliflozin and metformin) - Risk of Lower Limb AmputationSeptember 6, 2017 · Drugs
Other DINs named INVOKAMET
- DIN 02455404 · Marketed
- DIN 02455420 · Marketed
- DIN 02455455 · Marketed
- DIN 02455412 · Cancelled Post Market
- DIN 02455447 · Cancelled Post Market